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Available online 12 December 2015Obesity,metabolic syndrome (MetS) and type 2 diabetes (T2D) are associatedwith decreased cognitive function.
While weight loss and T2D remission result in improvements inmetabolism and vascular function, it is less clear
if these beneﬁts extend to cognitive performance. Here, we highlight the malleable nature of MetS-associated
cognitive dysfunction using a mouse model of high fat diet (HFD)-induced MetS. While learning and memory
was generally unaffected in mice with type 1 diabetes (T1D), multiple cognitive impairments were associated
with MetS, including deﬁcits in novel object recognition, cued fear memory, and spatial learning and memory.
However, a brief reduction in dietary fat content in chronic HFD-fed mice led to a complete rescue of cognitive
function. Cerebral blood volume (CBV), a measure of vascular perfusion, was decreased duringMetS, was associ-
ated with long term memory, and recovered following the intervention. Finally, repeated infusion of plasma
collected fromage-matched, low fat diet-fedmice improvedmemory inHFDmice, andwas associatedwith a dis-
tinctmetabolic proﬁle. Thus, the cognitive dysfunction accompanyingMetS appears to be amenable to treatment,
related to cerebrovascular function, and mitigated by systemic factors.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Diabetes has reached epidemic proportions, and projected rates pre-
dict that nearly 600 million people throughout the world will have dia-
betes within the next 20 years (Guariguata et al., 2014). Type 2 Diabetes
(T2D), characterized by obesity and insulin resistance (IR), accounts for
over 90% of all diabetes incidence (Engelgau et al., 2004). Aside from tra-
ditional complications, T2D poses an additional health risk in the form
of cognitive decline and dementia. While learning and memory is gen-
erally unaffected during type 1 diabetes (T1D) (Brands et al., 2005), in-
dividuals with T2D often demonstrate multiple cognitive impairments
(Kodl and Seaquist, 2008) and their risk of developing dementia is
signiﬁcantly increased compared to non-diabetic individuals (Cheng
et al., 2012). Furthermore, obesity, IR and metabolic syndrome (MetS)
are also associated with decreased cognitive function and an increased
risk of dementia even in the absence of overt diabetes (Baker et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010; Schrijvers et al., 2010).
Sedentary lifestyle and caloric excess are the primary contributors to
obesity, which in turn is the major modiﬁable risk factor for MetS and
T2D (Ershow, 2009). Thus, diet-induced obesity comprises a critical
risk factor for the development of cognitive impairment. Weight loss
is associated with improvements in general metabolism, vascular func-
tion and cardiovascular mortality (Bigornia et al., 2010; Sjöström et al.,
2012). While less clear, evidence suggests that the beneﬁts of weight
loss may also extend to cognitive performance (Espeland et al., 2014)
and the risk of developing dementia (Siervo et al., 2011). In addition
to an inverse association between IR andmemory, a possible association
between improved insulin sensitivity and improved cognition would
suggest that IR plays an important role during cognitive decline
(Brinkworth et al., 2009; Witte et al., 2009). Thus, lifestyle changes
such as weight loss may represent an effective therapeutic approach
to preventing or ameliorating cognitive decline due to their established
beneﬁts on insulin sensitivity and endothelial function (Blumenthal
et al., 2010; Mavri et al., 2011; Rudofsky et al., 2011). However, con-
trolled long-term studies in humans are challenging, and the mecha-
nisms of action remain undetermined.
While the precise biologicalmechanisms bywhich obesity andweight
loss affect cognitive function are unclear, several plausible pathways exist,
including oxidative stress, inﬂammation,metabolic impairments and vas-
cular dysfunction (Bruce-Keller et al., 2009). Of these potential mecha-
nisms, cerebrovascular function represents an intriguing potential link
between diabetes and cognition, as individuals with T2D show deﬁcits
in themaintenance and regulation of cerebral bloodﬂow(CBF) compared
to non-diabetic controls (Kim et al., 2008; Novak et al., 2006).
Multiple studies have demonstrated varying neurobiological deﬁcits
and cognitive impairments in rodent models of obesity, IR and diabetes
(Gault et al., 2010; Li et al., 2002; Stranahan et al., 2008a, 2008b;
Winocur et al., 2005). In the present study, we employed a commonly
used mouse model of chronic high fat diet (HFD) consumption in
order to assess whether the cognitive impairments associated with
MetS can be mitigated. The prevalence of cognitive impairment is
higher in women (Hebert et al., 2013), and while age is the strongest
risk factor for cognitive decline and dementia, it has become increasing-
ly clear that cognitive decline in late life is due in large part to vascular
risk factors such as diabetes during middle age (Debette et al., 2011).
Therefore, we induced MetS through chronic administration of a HFD
in “middle aged” female mice and analyzed the metabolic, cognitive
and cerebrovascular effects of MetS during old age. We then tested
the restorative potential of weight loss and improvements in peripheral
metabolism on cerebrovascular function and cognition by reducing the
dietary fat content in HFD-fed mice over a one month period.
Given the established peripheral vascular impairments associated
with T2D and the importance of cerebrovascular function for cognition,
it is plausible that circulating factors could affect brain function during
T2D. In fact, past studies involving shared circulations suggest that sys-
temic factors canmodulate obesity and T2D (Coleman, 2010). Addition-
ally, there has been increased interest in the role of systemic factors in
modulating health during old age, as a series of studies have shown
that young blood has numerous rejuvenating properties (Loffredo
et al., 2013; Ruckh et al., 2012; Salpeter et al., 2013). These studies
strongly suggest that factors present in a young systemic circulation
are able to reverse certain aspects of aging, including brain function
(Katsimpardi et al., 2014; Villeda et al., 2014). For example, exposure
to young blood enhanced neuronal spine density and synaptic plasticity
(Villeda et al., 2014) and induced vascular remodeling and neurogenesis
(Katsimpardi et al., 2014) in oldmice. Additionally, pancreatic beta cells
exposed to a young systemic circulation demonstrate increased replica-
tion (Salpeter et al., 2013). To date, these experiments have all focused
on aging and age differences between donors and recipients, and the
therapeutic capacity of systemic factors has yet to be explored in the
context of speciﬁc disease states and age-matched donors andrecipients. Therefore, to assess whether similar cognitive beneﬁts ex-
tend beyond aging to the context of MetS, we tested the hypothesis
that repeated infusion of “healthy” plasma collected from age-
matched, low fat diet (LFD)-fed mice could improve cognitive function
in mice with MetS.
2. Materials and Methods
2.1. Experimental Animals and Diet
Wild type female mice on a C57BL/6 background (Jackson Labs)
were employed in this study. Female mice were used as the prevalence
of cognitive impairment is higher in women (Hebert et al., 2013). Addi-
tionally, vascular risk factors during middle age drive development of
dementia in later life (Debette et al., 2011). Therefore, mice were fed a
specialized diet beginning at 9 months of age, and metabolic and
cognitive analyses were carried out at 14 and/or 15 months of age.
T1D was induced by ﬁve days of sequential intraperitoneal low-dose
streptozotocin (STZ) injections, at 12 months of age, as described
(Johnson et al., 2011). Obesity and MetS were induced by administra-
tion of a high fat diet (HFD) (60% kcal from fat, Research Diets
D12492, New Brunswick, NJ, USA). Control mice (and T1D mice) were
fed an ingredient-matched low fat diet (LFD) (10% kcal from fat, Re-
search Diets D12450B). The constituent components of the employed
diets are shown as follows (Ingredient (grams in HFD; grams in LFD)):
Casein (200; 200), L-cystine (3; 3), corn starch (0; 315), maltodextrin
10 (125; 35), sucrose (68; 350), cellulose BW200 (50; 50), soybean oil
(25; 25), lard (245; 20), mineral mix S10026 (10; 10), di-calcium
phosphate (13; 13), calcium carbonate (5.5; 5.5), potassium citrate
(16.5; 16.5), vitamin mix V10001 (10; 10), choline bitartrate (2; 2)
and FD&C dye #1 (blue 0.05; yellow 0.05). Metabolic and behavioral
measures (with the exception of the water maze involving multiple
platform locations)were completed in one cohort ofmice, while a second
cohort was employed for the water maze involving multiple platform lo-
cations and cerebral blood volumemeasures, and a ﬁnal cohort employed
for the plasma infusion studies. All mice were housed on a 12 hour light/
dark cycle (5:00 AM–5:00 PM). Plasma samples for fasting metabolic
measures were taken at ~1:00 PM following a four hour fast. Periods of
4 to 6 h of fasting are considered to be adequate for a deﬁnition of fasting
in mice as it avoids massive reduction in body fat content and glycogen
stores (Mutel et al., 2011; Pacini et al., 2013). Behavioral tests were typi-
cally assessed beginning at ~9:00 AM. For adipose tissue measurements,
the left epididymal fat pad (visceral) and left inguinal fat pad (subcutane-
ous) were weighed. All procedures complied with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals and with
IACUC approval at Oregon Health & Sciences University.
2.2. Biochemical Measurements
For the glucose tolerance test, mice were administered an oral
gavage of glucose solution (2 mg/g body weight). For the insulin toler-
ance test, mice were intravenously injected with 0.75 U/kg of human
insulin (Gibco). Blood glucose was measured using a glucometer (One
Touch Ultra) at indicated time points. Plasma triglycerides (Cayman
Chemicals), free fatty acids (ZenBio), glucose, total cholesterol and
ketone bodies (Wako), and plasma insulin (Millipore) were mea-
sured following a four-hour fast. GLP-1 was measured using a com-
mercial ELISA (RayBioTech). Plasma protein levels of interferon-γ,
interleukin-1β, interleukin-6, KC/GRO (Cxcl1), interleukin-10,
interleukin-12p70 and tumor necrosis factor-α were assessed in a
sandwich immunoassay format (7-Plex assay kit) according to the
manufacturer's instructions (MesoScale Discovery). For glucose up-
take, mice were injected following a four hour fast with 0.75 μCi of
2-[1,2-3H (N)]-deoxy-D-glucose (Perkin Elmer), diluted in 100 μl of
0.25 g/ml glucose solution, via the tail vein. Twenty minutes after
injection, mice were intraperitoneally administered a lethal dose of
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ketamine (Sigma), 0.625 mg/ml acepromazine (Vetus Animal Health),
3.125 mg/ml xylazine (Sigma)), intracardially perfused with 20 ml of
0.9% Phosphate-Buffered Saline (PBS), and tissues were collected. For tis-
sue glucose uptake, 25–150mg of tissuewas homogenized in 4ml of PBS.
The following tissues were collected for glucose uptake: brain (cortex),
skeletal muscle (right quadriceps), liver (median lobe), visceral fat
(right epididymal pad), subcutaneous fat (right inguinal pad), and
brown adipose tissue (interscapular). Homogenates were transferred to
a scintillation vial, 1 ml of Optiphase scintillation ﬂuid (Perkin Elmer)
was added, and samples were measured on a liquid scintillation counter
(Beckman).
2.3. Behavioral and Cognitive Analyses
2.3.1. Activity Monitoring and Nest Building
Activity was monitored using infrared home-cage activity sensors
(Biobserve, St. Augustin, Germany). Mice were individually housed
and acclimated to the home-cage environment for three days prior to
activity monitoring. Activity counts (beam breaks) were measured
every second for two weeks and data were expressed as mean activity
count per hour. Nest buildingwasmeasured using an established proto-
col (Deacon, 2006). Brieﬂy, mice were individually housed in a clean
cage and provided two pressed cotton squares (Ancare, Bellmore, NY).
Photos of the home cage were taken 48 h later and visually rated by
four different blinded scorers on a 5-point nest rating scale.
2.3.2. Anxiety-Like Behavior
Exploratory and anxiety-like behaviors were assessed using the
open-ﬁeld. The open-ﬁeld consisted of a brightly lit square arena (L
40.6 × W 40.6 × H 40.6 cm). The light intensity in the center of the
open ﬁeldwas 100 lux.Micewere allowed to explore for 10min. Behav-
ioral performance was tracked and scored using an automated video
system (Ethovision 7.0 XT, Noldus). Exploratory behavior was analyzed
using total distance moved, and time spent in the more anxiety-
provoking center (10 × 10 cm) of the open ﬁeld was also analyzed.
2.3.3. Novel Object Recognition
Mice were placed into the square arena used during the open-ﬁeld
testing, and habituated to the open ﬁeld arena over two days, with
one 10-minute trial per day. On the third day, mice were exposed to
the arena containing two identical objects (small orange hexagonal
prisms) placed 15 cm from the adjacent walls and 10 cm apart for
15 min. On day four, one of the identical objects (“familiar”) was re-
placedwith a novel object (small green triangular prism) of identical di-
mensions. During the open-ﬁeld and novel object recognition tests,
mice were placed into the arena at varying locations during each trial,
and the location of thenovel objectwas randomized to avoid procedural
bias. Clear visuospatial orientation to the object, within 2 cm proximity,
as well as physical interaction with the object was coded as exploratory
behavior, and the percent time spent exploring the novel versus familiar
object was calculated.
2.3.4. Spatial Learning and Memory in the Water Maze
Thewatermaze consisted of a circular pool (diameter 140 cm), ﬁlled
with opaquewater (white chalk added, 24 °C) divided conceptually into
four quadrants. Mice were given two sessions per day (separated by
three hours) consisting of two trials each (separated by 5 min), over
the course of ﬁve days (2 days “Visible Platform” followed by 3 days
“Hidden Platform”). Mice were ﬁrst trained to locate an “escape” plat-
form (Plexiglas circle, 6 cm radius) submerged 2 cm below the surface
of the water, by the use of a cue (a colored cylinder, 2.5 cm radius,
8 cm height) during the “Visible Platform” trials. Mice were removed
from the pool after locating the platform and remaining on it for 3 s.
Mice were inserted in the maze at varying locations during each trial
to avoid procedural bias, and during the Visible Platform trials, thelocation of the platform was moved for each session between the four
quadrants to avoid procedural biases in task learning. Subsequent to
the “Visible Platform” trials, mice were trained to locate the platform
sans cue during the “Hidden Platform” trials, which required the mice
to rely on extra-maze cues for spatial reference and orientation. Extra-
maze cues consisted of four large (50 × 50 cm) cues of different shapes
and color combinations, positioned at the borders of the four quadrants.
The platformwas not rotated during theHidden Platform trials, remain-
ing in the “Target” quadrant. Spatial memory retention was assessed
24 h following the conclusion of the fourth session of “Hidden Platform”
training, as well as 72 h following the ﬁnal “Hidden Platform” training
session. The submerged platformwas removed and spatial memory re-
tention assessed during these “Probe” trials by calculating the cumula-
tive distance from the target.
2.3.5. Spatial Learning and Memory in the Water Maze (Varied Platform
Locations)
Following ﬁve months of diet, mice were given three days of spatial
memory water maze testing similar to as described above. However, in
this protocol, the location of the platformwas changed daily. Mice were
given two sessions per day (separated by three hours) consisting of two
trials each (separated by 5min). Upon completion of the ﬁrst three days
of testing, a randomly assigned subset of HFD mice was switched to a
low fat diet. One month later, all mice were re-tested using the same
protocol described above, with three new hidden platform locations.
For plasma infusion experiments, the same experimental design was
followed, except in this case the mice received one day of baseline test-
ing followed by multiple plasma infusions and two additional testing
days with new hidden platform locations.
2.3.6. Fear Learning and Cued Fear Memory
In this task, mice learned to associate a conditioned stimulus (CS,
e.g. the environmental context, or a discrete cue — tone) with a mild
foot shock (unconditioned stimulus, US). Freezing, deﬁned as
somatomotor immobility with the exception of respiration, is con-
sidered a post-exposure fear response, and is a widely used indicator
of conditioned fear (Maren, 2001). Mice were trained and tested
using a Med Associates mouse fear conditioning system (PMED-
VFC-NIR-M, Med Associates, St. Albans, Vermont) utilizing Med As-
sociates VideoFreeze automated scoring system. Mice were placed
inside the fear conditioning chamber, and chamber lights were
turned on at zero seconds, followed by a 160 second habituation pe-
riod and a subsequent 30-second (80 dB) tone (cue). A 2-second
0.35 mA foot shock was administered at 188 s, co-terminating with
the tone at 190 s. This series was repeated for a total of four times.
Twenty-four hours later, mice were exposed to a modiﬁed environ-
ment (scented with vanilla extract, novel ﬂoor texture covering the
shock-grid, and rounded walls), allowed to habituate to it for 160 s,
and were then exposed to the sound cue for a second period of 30 s.
This series was repeated a total of four times. Motion during shock dur-
ing the training day was measured to account for sensor–motor differ-
ences in response to the aversive stimulus. Cued fear memory was
determined as the percent time spent freezing in response to the tone
(cue).
2.4. Cerebral Blood Volume (CBV), Vascular Casting and Vessel Analyses
To monitor changes in vessel diameter and vascular perfusion
(volume of blood-perfused vessels, referred to as cerebral blood vol-
ume (CBV) throughout the manuscript) in vivo, we used optical
microangiography (OMAG), an imaging technique based on optical
coherence tomography (OCT) (Jia et al., 2011). We used OMAG be-
cause it allows for in vivo, high-resolution, non-invasive quantiﬁca-
tion of CBV in mouse brain through an intact skull in real time (Jia
et al., 2009). CBV was calculated based on endogenous light scatter-
ing from moving blood cells within brain vessels. Brieﬂy, mice were
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at 37 ± 0.5 °C using a warm water pad. The skin over the skull was
reﬂected, the cortex illuminated through the skull at 1310 nm, and
the resulting backscattered and reference light detected to produce
spectral interferograms. A ﬁnal volume data cube is constructed
fromwhich the three-dimensional OMAG structural and ﬂow images
are computed. In our study, volumetric imaging data were collected
by scanning the probe beam through a 1000 × 500 × 512-voxel cube,
representing 2.5 × 2.5 × 2 mm3 (x–y–z) of tissue. Corresponding
OMAG images of the same area of the brain (branch of the middle ce-
rebral artery) were aligned for quantiﬁcation of CBV before and after
the intervention, as previously described (Siler et al., 2015). OMAG
images were rendered in the 3-D software AMIRA (FEI) and analyzed
for mean pixel intensity changes over time using ImageJ. For vessel
diameter measurements, average vessel diameters were measured
for each branching segment of the MCA within the scan area, and
pixel intensity histograms were generated using ImageJ.
For vascular casting, mice were deeply anesthetized with a keta-
mine–xylazine–acepromazine cocktail and immediately perfused
through the left ventricle at 4 ml/min, ﬁrst with 20 ml PBS containing
heparin (25 U/ml), followed by 20 ml 4% formalin in PBS, followed by
5ml of the polyurethane PU4ii (vasQtec, Zurich, Switzerland). The char-
acteristics of this castingmaterial have previously been described in de-
tail (Krucker et al., 2006). Brains were immediately removed and cured
in 4% formalin for 48 h and then transferred to 30% sucrose for 48 h.
Casted brains were then coronally sectioned at 50 μm into two series
using a cryostat (Microm HM505E, MICROM International GmbH,
Walldorf, Germany). Images were taken at 10× magniﬁcation using
an Olympus IX81 confocal microscope equipped with Slidebook soft-
ware (3i, Ringsby, CT, USA). Vessel territories analyzed include areas
ranging from 500 μm rostral and 500 μm caudal of Bregma 1.94 mm
(prefrontal cortex) or Bregma−1.82 (hippocampus). Z-stack images
taken within these areas represented a 3D area of analysis with the fol-
lowing dimensions: 2.56 × 0.65 × 1.0 mm. Vessel diameter and volume
were analyzed using 4Quant (Zurich, Switzerland) and Amira (FEI,
Houston, TX, USA) software. For analyses designed by 4Quant, a Gauss-
ian ﬁlter and threshold were applied to all images and several morpho-
logical operations were used to remove spurious voxels and better
connect the structures. Physically contiguous vessels were identiﬁed
with component labeling on the segmented image. The main regions
of the network were extracted and a thickness analysis was performed
by ﬁtting the largest sphere in each portion of the vessel which then
corresponds to its local diameter, similar to previously described
(Hildebrand and Rüegsegger, 1997). From the thickness map, a ridge
was identiﬁed which shows the skeleton of the vessel network, which
was then labeled and regrown into the original structure. The densities
corresponding to various regions and vessel diameters were then calcu-
lated from the territories of the Voronoi Tessellation. For analyses per-
formed using Amira software, mean vessel diameter, volume and
branching were measured using the proprietary XSkeleton feature.
2.5. Plasma Infusion and Metabolomics
Blood was collected from 34–50 female mice (“donor mice”), 15
months of age, into EDTA-coated tubes at time of death. Beginning at 9
months of age, donor mice were administered either a high fat or low-
fat diet for 6 months prior to plasma collection. Recipient T2D mice
were 15month old femalemice, as described above. Plasmawas generat-
ed by centrifugation (3000× g, 10 min at 4 °C) of freshly collected blood
and aliquots were stored at−80 °C until use. Prior to administration,
plasma was pooled and dialyzed in PBS overnight at 4 °C using 3.5-kDa
D-tube dialyzers (EMDMillipore) to remove EDTA, as described (Villeda
et al., 2014). Mice were systemically treated with plasma (100 μl per in-
jection) via intravenous injection ﬁve times over the course of 10 days
(injected every other day at ~8:30 AM). Injections and cognitive testing
were carried out by investigators blinded to treatment groups.The untargeted metabolomics analysis was performed on plasma
samples collected from HFD recipient mice 24 h following repeated in-
fusion of donor plasma and completion of cognitive testing. Unbiased
metabolomics proﬁling was completed as previously described with
minor changes (Kirkwood et al., 2013). Brieﬂy, liquid chromatography
(LC) was performed on a Shimadzu Nexera systemwith a phenyl-3 sta-
tionary phase (Inertsil Phenyl-3, 4.6 × 150mm, Phenomenex, Torrance,
CA) coupled to a quadrupole time-of-ﬂight mass spectrometer (Q-TOF)
(AB SCIEX, Triple TOF 5600) operated in information dependent MS/MS
acquisition mode. Samples were ordered randomly, including multiple
quality control samples, and automatic mass calibrations were per-
formed every hour. Samples were run in positive and negative ion
modes. Column temperature was held at 50 °C and samples at 10 °C.
Untargeted metabolomics data was processed using MarkerView
and Peakview software (AB SCIEX) and the web-based metabolomic
data processing toolMetaboanalyst (Xia andWishart, 2011). Signiﬁcant
metabolites were deﬁned by a Student's t-test and subsequent p-value
cutoff (p b 0.05). Metabolite identiﬁcation was based on mass error,
MS/MS fragment ions, and when possible comparison to an authentic
standard retention time. LipidView software (AB Sciex) and the online
LipidMaps, METLIN and Human Metabolome Database (HMDB) me-
tabolite databases were used forMS andMS/MSmatching. Manyme-
tabolites were further conﬁrmed with retention time by comparison
to authentic standards from an in-house library containing 619 me-
tabolite standards (IROA Technologies, Bolton, MA). For hierarchical
clustering, pathway impact and random forest analyses, the online
tool Metaboanalyst was used. For pathway impact and random forest
analyses, all 298 identiﬁed metabolites were included. For heatmap
analysis, only signiﬁcantly altered features were analyzed and data
was organized using a Euclidean distance map and complete cluster-
ing algorithm. For random forest and pathway impact analyses, data
were ﬁltered using the interquantile range (IQR) function and scaled
using auto-scaling, in which values are mean-centered and divided
by the standard deviation of each variable. For the random forest
analysis, the number of predictors to try for each node was set to
the square root of the total number of variables and the number of
trees to grow was set to 5000. For the pathway impact analysis, the
parameters were set to ‘global test’ and ‘Relative Betweenness
Centrality’, a node centralitymeasurewhich reﬂectsmetabolic pathway
‘hub’ importance.
2.6. Statistical Analyses
Data are expressed as mean ± standard error. Multiple groups
and/or multiple time points were analyzed using one-way ANOVA
(groups = HFD, LFD, and HFD–LFD) using Graph Pad Prism (San
Diego, CA), or repeated measures ANOVA (time × groups) using
SPSS software (Chicago, IL). To assess potential correlations, two-
tailed Pearson correlations were generated using GraphPad Prism
software. For correlation matrices, Pearson's r rank correlation coefﬁ-
cients were computed using z-score transformed values. Statistically
signiﬁcant correlations were determined using an error probability
level of p b 0.05 corrected by a false discovery rate (FDR) analysis.
3. Results
3.1. HFD-Induced MetS; Weight Loss and Improvements in Metabolism
Following a Reduction in Dietary Fat Content
To model the progression of obesity, insulin resistance (IR) and
metabolic syndrome (MetS), mice were fed a high fat diet (HFD) over
the course of six months. To test the restorative potential of weight
loss, a subset of HFD mice were administered a one month reduction
in dietary fat content following ﬁve months of HFD (hereafter referred
to as HFD–LFD) (Fig. 1A). Substantial group differences in body weight
(F(2,23) = 7.263, p = 0.004, repeated measures ANOVA), visceral
Fig. 1.HFD-InducedMetS; Restoration ofMetabolism via a Short-TermReduction inDietary Fat Content. (A) Experimental Design.MetSwas induced in “middle aged”mice (9months) via
administration of a high fat diet (HFD) for 6months. A subset of HFDmicewere given an intervention (“HFD–LFD”) by switching to an ingredient-matched low fat diet (LFD) at 14months
of age (light blue triangle). Behavioral testing, cerebrovascular imaging, and biochemical analyseswere carried out at 14 and 15months of age (white triangle). (B)Mice fed a high fat diet
become obese; HFD–LFD mice lose substantial body weight following a reduction in dietary fat content (week 20). Body weight was measured bi-weekly over the course of diet admin-
istration. (C) HFDmice gain adipose tissue mass; fat loss following a reduction in dietary fat content. Adipose tissue weight was measured from the left visceral (gonadal) and left subcu-
taneous (inguinal) fat pads. (D–E) Glucose and insulin are elevated during MetS and reduced following a reduction in dietary fat content. Plasma glucose and insulin were measured
following a four hour fast. (F–G)Chronic HFD consumption impairs glucose tolerance; improvement following the reduction in dietary fat content. (F) Blood glucosewas seriallymeasured
following an oral gavage of glucose and (G) area under the curve (AUC) was calculated. (H) Insulin sensitivity is decreased in HFDmice and improves following a reduction in dietary fat
content. Blood glucose was serially measured after an intraperitoneal injection of insulin. (I) Diabetic dyslipidemia during MetS; reduced plasma lipids following the diet intervention.
Plasma triglycerides (TG), cholesterol, and free fatty acids (FFA)weremeasured following a four hour fast. (J–K) Brain and peripheral tissue glucose uptake is reduced duringMetS. Uptake
of [3H] 2-deoxyglucosewasmeasured 20min following intravenous injection. Heatmaps (J) showing uptake in various organs. Colors represent groupmean glucose uptake as a percent of
LFD controls. (K) Total [3H] 2-deoxyglucose uptake in counts perminute (CPM) per gram of tissue. *p b 0.05, **p b 0.01 compared to LFD, ^p b 0.05, ^^p b 0.01, #p=0.066 compared to HFD,
ANOVA, followed by Tukey'smultiple comparison test. (B, F,H repeatedmeasures ANOVA). (C–K, measurements taken at 15months of age). (B, n=6–11; C–D, n=10–15; E–K, n=5–9).
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ous adipose tissue mass (F(2,35) = 31.81, p b 0.001, ANOVA) were ob-
served over the course of the study (Fig. 1B–C). Following the
reduction in dietary fat content, HFD–LFD mice showed considerable
decreases in bodyweight (weeks 22–24, F(2,23)= 12.452, p=0.002, re-
peated measures ANOVA), and visceral (HFD vs HFD–LFD, p = 0.003,
Tukey's multiple comparisons test (Tmct)) and subcutaneous adipose
tissue mass (HFD vs HFD–LFD, p b 0.001, Tmct), compared to HFD
mice (Fig. 1B–C). The substantial weight loss in HFD–LFDmice appeared
to be a result of decreased caloric intake (Fig. 2A) (F(2,37) = 14.42, p b
0.001, ANOVA; HFD vs HFD–LFD, p b 0.001, Tmct) rather than reduced
food consumption (Fig. 2B) (F(2,36) = 0.694, p= 0.506, ANOVA) or in-
creased activity (Fig. 2C–F). AlthoughHFDmice showed signiﬁcantly re-
duced activity compared to LFD mice (F(2,10) = 6.758, p = 0.0139,
ANOVA; HFD vs LFD, p = 0.013, Tmct), total activity during the active
(dark) cycle did not signiﬁcantly differ between HFD and HFD–LFD
mice following the reduction in dietary fat content (Fig. 2C–F) (p =
0.503, Tmct).HFD mice demonstrated several hallmarks of MetS, all of which
signiﬁcantly improved following the reduction in dietary fat content
(Fig. 1D–I), including hyperglycemia (F(2,38) = 21.19, p b 0.001,
ANOVA; HFD vs HFD–LFD, p = 0.033, Tmct), hyperinsulinemia
(F(2,22) = 4.745, p = 0.0194, ANOVA; HFD vs HFD–LFD, p = 0.031,
Tmct), impaired glucose tolerance (F(2,18) = 17.843, p b 0.001, repeated
measures ANOVA; HFD vs HFD–LFD, p= 0.002, Tmct), decreased insu-
lin sensitivity (F(2,18) = 6.579, p = 0.007, repeated measures ANOVA;
HFD vs HFD–LFD, p = 0.019, Tmct), and dyslipidemia (triglycerides,
F(2,20)=5.978, p=0.009; HFD vsHFD–LFD, p=0.032, Tmct; cholester-
ol (F(2,20) = 35.96, p b 0.001; HFD vs HFD–LFD, p b 0.001). Measures of
glucose metabolism, adiposity, and dyslipidemia positively correlated
with one another. Glucose uptake in various tissues positively correlat-
ed with one another, and negatively correlated with measures of
glucose metabolism, plasma lipids, and degree of adiposity (Fig. 3). Al-
though plasma glucose concentrations were lower in HFD–LFD com-
pared to HFD mice, they remained signiﬁcantly elevated compared to
LFD mice (LFD vs HFD–LFD, p = 0.003, Tmct), while insulin levels
Fig. 2. Caloric Intake is Reduced in HFD–LFDMice; HFD and HFD–LFDMice Are Less Active. (A–B) Caloric intake is reduced in HFD–LFDmice despite a similar per gram daily food intake.
(A) Total daily caloric intake (kcal) was calculated based on daily food intake. (B) Food intake was measured for four days immediately following the diet intervention. (C–F) Home cage
activity is reduced in HFD and HFD–LFD mice. (C) Total activity was calculated as the mean area under the curve during the 12 hour active (dark) cycle. (D–F) Mean activity patterns of
(D) control, (E) HFD and (F) HFD–LFD mice. Individually housed mice were monitored using infrared sensors for three days prior, and ten days after, the reduction in dietary fat content.
*p b 0.05, **p b 0.01 compared to LFD, ^p b 0.05, ^^p b 0.01 compared to HFD, ANOVA, followed by Tukey's multiple comparison test. (A–B, n = 11–15) (C–F, n= 4–5).
31L.A. Johnson et al. / EBioMedicine 3 (2016) 26–42were slightly lower (LFD vs HFD–LFD, p=0.048, Tmct), suggesting some
lasting deﬁciencies in metabolism (Fig. 1D–E). HFD mice also displayed a
pattern of reduced glucose uptake in the brain (F(2,21)= 7.482, p=0.004,
ANOVA), aswell as in several peripheral organs (Fig. 1J–K) including skel-
etal muscle (F(2,21) = 9.117, p=0.0013, ANOVA), visceral adipose tissue
(F(2,21) = 13.32, p b 0.001, ANOVA), subcutaneous adipose tissue
(F(2,21) = 9.237, p = 0.001, ANOVA), and brown adipose tissue
(F(2,21) = 6.825, p= 0.005, ANOVA). Following the reduction in dietary
fat content, fasting glucose uptake signiﬁcantly increased in skeletal mus-
cle (LFD vsHFD–LFD, p=0.018, Tmct), visceral adipose (LFD vsHFD–LFD,
p = 0.011, Tmct), subcutaneous adipose (LFD vs HFD–LFD, p = 0.014,
Tmct), and brown adipose tissue (LFD vs HFD–LFD, p = 0.0135, Tmct)
(Fig. 1J–K). In the brain, there was a trend towards increased glucose up-
take in HFD–LFD compared to HFD mice, but this did not reach signiﬁ-
cance (Fig. 1K) (HFD vs HFD–LFD, p= 0.066, Tmct).
Inﬂammation has been proposed as a possible causative link be-
tween diabetes and cognitive dysfunction (Chung et al., 2015; Novak
et al., 2011). Circulating concentrations of the several criticalinﬂammatory markers, including IL-12p70, IL1β, TNFα, and IFNγ —
while generally increased in HFD mice, did not signiﬁcantly differ
from LFD controls or the intervention group (Table 1). However, plasma
CXCL1 levels were signiﬁcantly increased in HFD compared to LFDmice
(F(2,19)=9.776, p=0.001, ANOVA;HFD vs LFD, p=0.002, Tmct),while
HFD–LFD mice showed signiﬁcantly lower concentrations of both
CXCL1 (HFD vs HFD–LFD, p = 0.015, Tmct) and IL-6 (F(2,19) = 7.052,
p = 0.006, ANOVA; HFD vs HFD–LFD, p = 0.004, Tmct) compared to
HFDmice (Table 1), suggesting that potential anti-inﬂammatory chang-
es accompanied the reduction in dietary fat content. Brain-derived neu-
rotrophic factor (BDNF) has also been suggested as a link between
diabetes and brain function (Fujinami et al., 2008). While we noted a
trend of decreased BDNF levels in the hippocampus (F(3,27) = 2.253,
p= 0.105, ANOVA) and cortex (F(3,27) = 1.493, p= 0.239, ANOVA) of
HFD mice compared to all other groups, these differences did not
reach signiﬁcance (Table 1). Similarly, the neuropeptide glucagon-like
peptide (GLP-1) also represents a potential link between diabetes and
cognitive function, particularly in the background of a high fat diet
Fig. 3. Correlation Matrix of Physiological and Behavioral Measures. Measures of glucose metabolism, adiposity and dyslipidemia positively correlate with one another. Glucose uptake in
various tissues positively correlates with one another, and negatively correlates with measures of glucose metabolism, plasma lipids, and degree of adiposity. The correlation matrix of
physiological and behavioral measures is based on Pearson's linear correlation (Pearson's r rank correlation coefﬁcients were computed using z-score transformed values). Black circles
represent signiﬁcant correlations after false discovery rate correction (Benjamini Hochberg method). Abbreviations (speciﬁc measure analyzed in parentheses): BW, body weight; Br
Fat, brown fat; CH, cholesterol; Cued, cued memory (average time freezing in response to cue); FFA, free fatty acids; Nesting, nesting score; OGTT, oral glucose tolerance test (area
under the curve); SC Fat, subcutaneous fat; Recog, object recognition memory (time spent exploring novel object); Spatial, spatial memory (cumulative distance to platform during
72 h memory probe); TG, triglycerides; V Fat, visceral fat.
Table 1
Physiologic and Metabolic Parameters in Experimental Mice.
LFD (n) T1D (n) HFD (n) HFD–LFD (n)
Physiological measures
Body weight (g) 28.68 ± 1.204a 14 24.44 ± 2.040b 8 48.09 ± 4.300c 13 28.33 ± 0.590a 12
Visceral fat (g) 0.999 ± 0.643a 14 0.346 ± 0.179b 8 4.556 ± 4.036c 13 0.988 ± 0.407a 11
SC fat (g) 0.458 ± 0.186a 14 0.288 ± 0.122b 8 2.553 ± 1.245c 13 0.601 ± 0.209a 11
Plasma markers
Glucose (mg/dl) 74.8 ± 15.76a 15 408.6 ± 74.11b 8 123.5 ± 19.15c 14 102.7 ± 25.77d 12
Insulin (ng/ml) 0.755 ± 0.433a 9 b.d. 8 3.467 ± 3.719b 9 0.360 ± 0.228c 7
TC (mg/dl) 70.51 ± 6.06a 9 119.5 ± 28.4b 7 105.0 ± 14.34b 8 67.03 ± 5.12a 6
TG (mg/dl) 35.01 ± 3.94a 9 48.61 ± 11.20b 7 46.49 ± 11.71b 8 37.18 ± 6.57a,b 6
FFA (μM) 172.7 ± 38.32a 7 253.3 ± 79.78b 7 211.1 ± 79.78a,b 8 175.6 ± 31.35a 6
KB (μM/l) 98.85 ± 24.02a 8 352.8 ± 225.6b 7 182.8 ± 127.0a,b 7 120.1 ± 35.15a 5
GLP-1 (pg/ml) 8.724 ± 1.484a 6 n.d. 5.888 ± 2.00a 7 8.002 ± 2.822a 5
BDNF (pg/mg protein)
Hippocampus 129.8 ± 11.87a 8 146.3 ± 42.49a 9 91.03 ± 18.13a 9 153.6 ± 32.38a 6
Cortex 152.3 ± 19.72a 8 203.7 ± 113.7a 9 144.4 ± 20.43a 9 163.0 ± 32.69a 6
Plasma inﬂammatory markers
IFN-γ (pg/ml) 1.986 ± 1.212a 8 n.d. 1.912 ± 1.165a 9 1.292 ± 0.225a 6
IL-10 (pg/ml) 15.47 ± 6.28a 8 n.d. 17.23 ± 5.77a 9 16.73 ± 12.26a 6
IL-12p70 (pg/ml) 42.84 ± 24.50a 8 n.d. 44.70 ± 25.56a 9 36.61 ± 25.80a 6
IL-1b (pg/ml) 1.218 ± 1.318a 8 n.d. 1.958 ± 2.206a 9 0.865 ± 0.993a 6
Cxcl1 (pg/ml) 135.9 ± 33.04a 8 n.d. 236.2 ± 68.73b 9 150.0 ± 26.18a 6
TNFα (pg/ml) 2.829 ± 3.965a 8 n.d. 3.052 ± 4.119a 9 6.127 ± 4.178a 6
IL-6 (pg/ml) 61.81 ± 28.30a 8 n.d. 87.30 ± 43.03a 9 21.03 ± 17.64b 6
b.d., below detection; BDNF, brain derived neurotrophic factor; Cxcl1, chemokine (C-X-C motif) ligand 1; FFA, free fatty acids; GLP-1, glucagon-like peptide 1; HFD, high fat diet; IFN-γ,
interferon-γ; IL-1b, interleukin-1β; IL-6, interleukin-6; IL-10, interleukin-10; IL-12p70, interleukin-12p70; KB, total ketone bodies; LFD, low fat diet; n.d., not determined; SC, subcutane-
ous; TC, total cholesterol; TG, triglycerides; TNFα, tumor necrosis factor-α. All parameters were measured at 15 months of age (following 6 months on diet). Plasma markers were
measured following a 4 h fast. Means without common superscript differ signiﬁcantly (p b 0.05, ANOVA followed by Tukey's multiple comparisons test).
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33L.A. Johnson et al. / EBioMedicine 3 (2016) 26–42(Lennox et al., 2014). We observed a decrease in plasma GLP-1 concen-
trations in HFD compared to both LFD and HFD–LFD mice (Table 1),
however this difference did not reach signiﬁcance (F(3,15) = 3.175,
p= 0.071, ANOVA).
3.2. Amelioration of Cognitive Impairments Following a Reduction in
Dietary Fat Content
We next evaluated the effects of MetS and a reduction in dietary fat
content on cognitive performance. Deﬁcits in natural rodent behaviors
such as nest building may reﬂect disrupted activities of daily living in
people with cognitive impairment (Deacon, 2012). We observed that
HFD mice constructed less complex nests than their LFD counterparts
(F(2,22) = 10.25, p b 0.001, ANOVA; HFD vs LFD, p b 0.001, Tmct),
and normal nest building behavior was restored in HFD–LFD miceFig. 4.MetS Results inMultiple Cognitive and Behavioral ImpairmentsWhich Are Rescued via a
Representative photos andmean scores of nests formed 48 h after nesting material is provided.
novel object (box2, striped bars) 24 h after exposure to a familiar object (box 1, open bars), as sh
deﬁciencies in spatial learning andmemory. Latency to ﬁnd a visible (“Task Learning”, left) or h
timing (in hours) of tests of long-termmemory retention (C–E) are noted by the circled number
displaying swim patterns during amemory probe trial 72 h after the last training session. Platfo
long-term spatial memorywasmeasured by calculating the cumulative distance from the targe
and thus lower cumulative distance values. (F) Fear learning is unaffected by MetS. Mice were
paired inHFDmice. Cued recallwas assessed bymeasuring freezing in response to the tone 24h
the intertone period. (H) A short-term reduction in dietary fat content improves spatial learning
maze protocol inwhich the location of a hidden platformwas varied daily (two sessions/day). F
low fat diet for onemonth (HFD–LFD), and allmicewere re-tested (sessions 7–12). (I) HFD–LFD
latency between trials separated by a short (5min) or long (3 h) delay. *p b 0.05, **p b 0.01 com
comparison test. (C, F, G, H repeated measures ANOVA). (A–G, n = 7–9) (H–I, n= 9–11).(Fig. 4A) (HFD vs HFD–LFD, p = 0.02, Tmct), although this behavior
may instead be explained by adiposity and heat regulation.We next ex-
amined novel object recognition. Following two acclimation periods,
mice were exposed to two identical objects and allowed to freely
explore. The time spent exploring each of the two identical objects did
not differ in any of the groups (Object 1 vs Object 2, LFD, t(8) = 0.416,
p = 0.689; HFD, t(8) = 1.156, p = 0.281; HFD–LFD, t(6) = 1.192,
p = 0.278, paired t-test) (data not shown). Twenty-four hours
later, mice were re-introduced to one of the previous familiar objects
and a novel object. LFD and HFD–LFD mice showed a robust prefer-
ence for the novel object (t(8) = 2.073, p = 0.01; t(6) = 3.549, p =
0.004, paired t-test, respectively), while HFD mice did not show a
preference (Familiar object vs Novel object, t(8) = 0.791, p =
0.441, paired t-test), suggesting impaired recognition memory
(Fig. 4B).Reduction in Dietary Fat Content. (A) Nesting behavior is disrupted by HFD-inducedMetS.
(B) Recognitionmemory is impaired in HFDmice. HFDmice fail to show a preference for a
own by video tracking (left panels) and time spent exploring eachobject. (C)MetS leads to
idden (“Spatial Learning andMemory”, right) escape platform during thewater maze. The
s. (D–E) Long-term spatialmemory is impaired inHFDmice. (D) Representative heatmaps
rm location during hidden training is noted by the dashedwhite circle. (E) The accuracy of
t platform location. Robust memory retention is reﬂected inmore accurate search patterns,
conditioned to associate a cue (tone) with a mild foot shock. (G) Cued fear memory is im-
after training. Therewere nodifferences in generalized fear, as indicated by freezing during
andmemory inHFDmice. Spatial learning andmemorywas tested using amodiﬁedwater
ollowing the ﬁrst round of testing (sessions 1–6), a subset of HFDmice were switched to a
mice showgains inmemory retention.Memory retentionwas calculated as thedecrease in
pared to LFD, ^p b 0.05, ^^p b 0.01 compared to HFD, ANOVA, followed by Tukey'smultiple
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Differences in vision, general task learning, anxiety or motor function
could affect performance in the water maze. However, there were no
group differences in the ability to locate a visible platform (Fig. 4C)
(F(2,22) = 1.875, p=0.178, repeated measures ANOVA) (Supplemental
Fig. 1A) (F(2,27) = 0.153, p= 0.860, repeated measures ANOVA), sug-
gesting that chronic HFD consumption does not affect task learning.
There were also no differences in anxiety-like behavior in the open-
ﬁeld test (Supplemental Fig. 1B) (F(2,22) = 0.220, p = 0.804, ANOVA),
and despite concerns that obesitymay affectmotor ability, swim speeds
did not signiﬁcantly differ during the water maze (Supplemental
Fig. 1C) (F(2,22) = 1.380, p = 0.273, ANOVA). Conversely, HFD mice
were diminished in their ability to locate a hidden escape platform, in-
dicating impairments in spatial learning (Fig. 4C, right) (F(2,22) =
7.166, p = 0.004, repeated measures ANOVA). Long-term spatial
memory retention was assessed in probe trials in which the plat-
form was removed and search patterns were analyzed. During
both the 24 and 72 hour probe trials, HFD mice showed less accurate
search patterns (Fig. 4D), as evidenced by an increase in the cumulative
distance from the platform (Fig. 4E) (24 h, F(2,22) = 4.235, p = 0.028,
ANOVA; HFD vs LFD, p = 0.043, HFD vs HFD–LFD, p = 0.044, Tmct;
72 h, F(2,22) = 4.889, p = 0.017, ANOVA; HFD vs LFD, p = 0.033, HFD
vs HFD–LFD, p= 0.025, Tmct).
To test fear learning and cued fear memory, mice were trained to
associate a cue (30 s tone) with a mild foot shock. All groups showed
similar learning (Fig. 4F) (F(2,22)= 0.400, p=0.675, repeatedmeasures
ANOVA) and response to the shock (Supplemental Fig. 1D) (F(2,22) =
0.154, p = 0.852, ANOVA) during the training day. However, HFD
mice showed a decreased cued memory when reintroduced to the
tone (Fig. 4G, tone) (F(2,22) = 3.955, p = 0.035, repeated measures
ANOVA; HFD vs LFD, p = 0.036, Tmct). This effect was not a result of
differences in generalized fear (Fig. 4G, intertone) (F(2,22) = 0.06,
p = 0.9417, ANOVA), and the MetS-associated impairment in cued
fearmemory was rescued following the reduction in dietary fat content
(Fig. 4G, tone) (HFD vs HFD–LFD, p= 0.038, Tmct).
To verify that the reduction in dietary fat content truly had a re-
storative effect on learning and memory, rather than simply being
due to a threshold effect (i.e. ﬁve vs six months of high fat diet),
we tested spatial learning and memory in an independent experi-
ment before and after the intervention. Following ﬁve months of
high fat diet, half of the HFD mice were randomly assigned to con-
tinue on high fat diet and half were administered the low fat diet in-
tervention. During the initial test, HFD mice showed signiﬁcant
impairments in spatial learning and memory in a task that involved
varied escape platform locations (Fig. 4H, left) (Sessions 3 and 4,
F(1,27) = 3.940, p = 0.047; Sessions 5 and 6, F(1,27) = 21.091, p b
0.001, repeated measures ANOVA). Following the additional
month, both LFD and HFD–LFD mice demonstrated superior perfor-
mance compared to HFD mice (Fig. 4H–I, right) (Sessions 11–12,
F(2,26) = 5.186, p = 0.013, repeated measures ANOVA; HFD vs LFD,
p = 0.021, HFD vs HFD–LFD, p = 0.028, Tmct). In particular, HFD
mice struggled to retain memory of the platform location over the
long delay (3 h) that separated the ﬁrst and second daily testing ses-
sions (Fig. 4I) (pre-intervention HFD vs LFD, t(27) = 2.202, p =
0.036, t-test; post-intervention, F(2,26) = 3.367, p = 0.040, ANOVA,
HFD vs LFD, p = 0.044, Tmct). In contrast, HFD–LFD mice showed
substantial improvements in memory retention, in particular during
the short delay (5 min) (Fig. 4I, right) (F(2,26) = 5.605, p = 0.009,
ANOVA; HFD vs HFD–LFD, p = 0.019, LFD vs HFD–LFD, p = 0.018,
Tmct).
We next asked if these cognitive deﬁcits were universal to diabetes,
or speciﬁc to the background of obesity, IR and MetS. To answer this
question, we compared the cognitive proﬁles of HFD mice to diet- and
age-matched siblings who were injected with streptozotocin (STZ), a
model of type 1 diabetes (T1D). In contrast to T2D, where deﬁcits in
memory are noted even in early stages of the disease (Ruis et al.,2009), T1D patients generally show modest neurological impairments,
and learning and memory are generally spared (Brands et al., 2005).
Similarly, our results in an age- and diet-matchedmodel of T1D showed
very modest effects on learning andmemory (Fig. 5). T1Dmice showed
profound peripheral metabolic impairments, including insulin deﬁcien-
cy, glucose intolerance, ketoacidosis and severe hyperglycemia
(Table 1). However, their cognitive performance on tasks of novel object
recognition (Fig. 5A) (Familiar object vs Novel object, LFD, t(8) = 2.073,
p = 0.01; T1D, t(6) = 3.232, p = 0.007, paired t-test), spatial learning
and memory (Fig. 5B) (F(1,14) = 0.754, p = 0.400, repeated measures
ANOVA), long term spatial memory (Fig. 5C–D) (24 h, t(14) = 1.490,
p = 0.157; 72 h, t(14) = 0.509, p = 0.619, t-test), fear learning
(Fig. 5E) (F(1,14) = 0.020, p= 0.889, repeated measures ANOVA), and
cued fear memory (Fig. 5F) (F(1,14) = 0.335, p = 0.572, repeated
measures ANOVA) was comparable to that of control mice. While
T1D mice were slightly slower in general task learning, as seen in
the visible portion of the water maze (Fig. 5B, left) (F(1,14) = 7.824,
p=0.015, repeatedmeasures ANOVA), they did not signiﬁcantly dif-
fer from LFD controls by the end of training (Session 3, LFD vs T1D,
t(14) = 0.679, p = 0.512; Session 4, LFD vs T1D, t(6) = 1.769, p =
0.099, t-test).3.3. Cerebral Blood Volume Declines During MetS, Recovers Following a
Reduction in Dietary Fat Content, and is Associated with Memory
To determine whether the cognitive impairments accompanying
MetS are associated with alterations in cerebrovascular function, we
measured cerebral blood volume (CBV) using optical microangiography
(OMAG). OMAG allows for 3D volumetric quantiﬁcation of blood-
perfused vessels in the brain, at the capillary level, through an intact
skull, in vivo and in real time (Jia et al., 2009). We focused our imaging
on pial vessels that receive blood supply from themiddle cerebral artery
(MCA), as the MCA supplies several areas of the frontal, parietal and
temporal cortices that play a role in the cognitive measures employed
in this study, in particular components of the spatial learning andmem-
ory task involving varied platform locations (Bell et al., 2009; Curtis and
D'Esposito, 2003; Haines, 2008; Postle, 2006; Smith and Jonides, 1999).
CorrespondingOMAG images of the same area of the brainwere aligned
for quantiﬁcation of CBV before and after the intervention. HFD mice
demonstrated reduced microvascular CBV in pial vessels within the an-
alyzed cortical area (Fig. 6A–C) (CBV ≤ 10 μM vessel diameter, F(3,31) =
4.654, p = 0.008, ANOVA; HFD (Image) vs LFD (Image), p = 0.009,
Tmct). Re-imaging of the same vessel territories, in the same HFD
mice, following the one month reduction in dietary fat content, re-
vealed a signiﬁcant increase in microvascular CBV, restoring CBV to
similar levels as in controls (Fig. 6C) (HFD (Image) vs HFD–LFD
(Re-image), ≤10 μM vessel diameter, p = 0.022; LFD (Re-Image) vs
HFD–LFD (Re-image), ≤10 μM vessel diameter, p = 0.787, Tmct).
Furthermore, spatial memory retention was positively correlated
with microvascular CBV (Fig. 6D) (r2 = 0.822, p b 0.001, Pearson).
This phenomenon was speciﬁc to memory, as general task learning
did not correlate with CBV (Supplemental Fig. 1E) (r2 = 0.001, p =
0.987, Pearson).
To determine if the alterations in CBVwere due to structural changes
such as vessel rarefaction or neovascularization, we created polyure-
thane casts of the cerebral vasculature (Fig. 7A–C). Analysis of six dis-
tinct regions critical for performance in the spatial learning and
memory water maze with varied platform locations (CA1, CA3, dentate
gyrus, and the prelimbic, infralimbic, and cingulate cortex) did not re-
veal any differences in vessel volume or degree of vessel branching
(Fig. 7D–I) (Volume, Hipp., F(2,7) = 0.991, p = 0.646; Volume, PFC,
F(2,7) = 0.620, p = 0.956; Branching, Hipp., F(2,7) = 0.328, p = 0.895;
Branching, PFC, F(2,7) = 0.540, p = 0.841, ANOVA). Taken together,
these data suggest that the observed changes in CBV are likely function-
al, rather than structural, in origin.
Fig. 5.Modest Cognitive Effects in a Model of Untreated Type 1 Diabetes. (A) Recognition memory is unaffected in mice with T1D (STZ treated). Twenty-four hours after exposure to a
familiar object (open bars), mice were exposed to a novel object (striped bars). Control LFD mice and T1D mice both preferentially explore the novel object, suggesting memory of
prior exposure to the familiar object. (B) T1D leads to slower task learning, but does not affect spatial learning and memory. Latency to ﬁnd a visible or hidden escape platform during
the water maze. The timing (in hours) of tests of long-term memory retention (C–D) are noted by the circled numbers. (C–D) Long-term spatial memory is unaffected in T1D mice.
(C) Representative heat maps, displaying swim patterns during a probe trial given 72 h after the ﬁnal water maze training session. The platform location during hidden training is
noted by the dashed white circle. (D) The accuracy of long-term spatial memory was measured by calculating the cumulative distance from the target platform location. (E–F) (E) Fear
learning and cued fear memory are unaffected by T1D. Mice were conditioned to associate a cue (tone) with a mild foot shock. (F) Cued memory was assessed by measuring freezing
in response to the tone 24 h after conditioning. Generalized fear is indicated by freezing during the intertone period. *p b 0.05, **p b 0.01 compared to LFD, ^p b 0.05, ^^p b 0.01 compared
to HFD, ANOVA, followed by Tukey's multiple comparison test. (B, E, F repeated measures ANOVA) (n= 7–9). LFD group data is reproduced from Fig. 2.
35L.A. Johnson et al. / EBioMedicine 3 (2016) 26–423.4. Infusion of LFD Plasma Mitigates Cognitive Impairments in HFD Mice
and is Associated with a Distinct Metabolic Proﬁle
Recent studies demonstrate remarkable neuro-restorative effects of
young blood in agedmice (Villeda et al., 2014; Katsimpardi et al., 2014).
We wished to test the hypothesis that plasma from LFD mice would
have a beneﬁcial effect on learning and memory, independent of age,
in HFD mice. Over the course of ten days, plasma collected from age-
and sex-matched sibling donors was repeatedly intravenously infused
into HFD recipients (Fig. 8A). Compared toHFDmicewho received plas-
ma collected from other HFD mice, those receiving plasma from LFD
mice performed signiﬁcantly better on a spatial learning and memory
task (Fig. 8B–C) (Day 7, F(1,16) = 4.996, p= 0.040, repeated measures
ANOVA; Day 7 Mean Latency, t(16) = 2.173, p = 0.045; Day 10,
F(1,16) = 10.153, p= 0.006, repeated measures ANOVA; Day 10 Mean
Latency, t(16) = 2.848, p = 0.012, t-test). This cognitive improve-
ment occurred independently of changes in body weight (t(16) =
0.153, p = 0.880, t-test), plasma glucose (t(16) = 0.511, p = 0.616,
t-test), ormotor function (t(16)= 0.131, p=0.898, t-test) (Supplemen-
tal Fig. 2A–C).
To evaluate potential metabolic pathways which could underlie the
observed improvements in learning andmemory in HFDmice following
exposure to LFD plasma, we used an untargeted metabolomicsapproach. Plasma collected from HFD recipient mice following comple-
tion of their ﬁnal cognitive test was analyzed using high-performance
liquid chromatography in combination with quadrupole time-of-ﬂight
mass spectrometry. We identiﬁed 243 metabolites (Supplemental
Table 1), of which 45 differed signiﬁcantly in abundance between HFD
mice receiving LFD versus HFD plasma (Fig. 8D). The proﬁle was domi-
nated by alterations in amino acid (AA) and lipidmetabolism. HFDmice
receiving LFD plasma showed lower concentrations of several AAs and
their metabolic byproducts, including methionine, proline, homoserine
and lysine. HFD mice receiving LFD plasma also showed higher concen-
trations of numerous glycerolipids (GL), in particular phosphatidylcho-
lines (PC) and phosphatidylethanolamines (PE) (Fig. 8D).
To generate a globalmetabolome view, and to examinewhether any
particular metabolic ‘hubs’ were affected, we performed a pathway
impact analysis using a relative-betweenness centrality measure. The
impact analysis conﬁrmed that the primary alterations were in AA and
glycerophospholipid (GPL) metabolism (Fig. 8E). Speciﬁcally, the
pathways most impacted by plasma infusion were GPL metabolism, ar-
achidonic acid metabolism, GL metabolism, cysteine and methionine
metabolism, lysine degradation, and glycosylphosphatidylinositol
(GPI) anchor biosynthesis (Fig. 8E). We then used a random forest
(RF) supervised class prediction model to determine the capacity of
themetabolome to accurately classifymice into their respective groups,
Fig. 6. Cerebral Blood Volume Declines During MetS, Recovers Following a Reduction in Dietary Fat Content, and is Associated with Memory. (A) Representative 3D images of cerebral
blood volume (CBV) in vessels supplied by the middle cerebral artery. CBV was measured through an intact skull using optical micro-angiography. Scale bar 1 mM. (B–C) HFD-induced
MetS is associated with decreased microvascular CBV, and a reduction in dietary fat content restores CBV to a similar level as controls. (B) Representative 2D-compressed images of
CBV before and after a reduction in dietary fat content. The top row shows an area of the cortical surface of a LFD mouse imaged after ﬁve months, and re-imaged after six months, of
low fat diet. The bottom row shows amouse fed a high fat diet for 5months (HFD), and then re-imaged following a onemonth reduction in dietary fat content (HFD–LFD). Microvascular
CBV increased inHFD–LFDmice, as highlighted by the dottedwhite line. Scale bar 100 μM. (C) CBVwithin vessels of various diameters before (“Image”) and after (“Re-Image”) the low fat
diet intervention. (D) Microvascular CBV positively correlates with cognitive performance in a spatial memory task. Memory retention is deﬁned as the change in latency to ﬁnd the
platform over a three hour period. Body weight is represented by symbol diameter. *p b 0.05, **p b 0.01, ANOVA, followed by Tukey's multiple comparison test. (D, two-tailed Pearson
correlation) (C–D, n= 8–9).
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tion. The RF predictor correctly stratiﬁed 8/9 HFD receiving HFD plasma
and 9/9 HFD receiving LFD plasma mice, for a cumulative predictive
accuracy of 94%. The RF analysis deﬁned the top 20 metabolites that to-
gether constitute the best predictors of group status, including numer-
ous GPLs with high predictive accuracy (Fig. 8F). Together, these data
indicate that repeated infusion of LFD plasma into HFD mice results in
cognitive improvement characterized by a distinct plasma metabolic
proﬁle.
4. Discussion
In the present study, we highlight the malleable nature of MetS-as-
sociated cognitive dysfunction using a mouse model of chronic high
fat diet (HFD) consumption.We show that a short-term reduction in di-
etary fat content results in improvements in peripheral metabolism, in-
creased cerebral blood volume (CBV), and substantial gains in cognitive
function in HFD mice. Additionally, we show that the administration of
plasma collected from low fat diet (LFD) mice improves cognitive func-
tion in HFD mice, suggesting the involvement of systemic factors.
Increased adiposity inmiddle age drives risk of dementia in later life
(Luchsinger and Gustafson, 2009) and the prevalence of cognitive
impairment is higher in women (Hebert et al., 2013). Therefore, we in-
duced obesity, IR and MetS in “middle aged” female mice (9 monthsold) via chronic administration of a high fat diet and assessedmetabolic,
vascular and cognitive effects during old age (14–15 months of age).
HFD mice demonstrated several hallmarks of MetS commonly seen in
human patients, including hyperglycemia, hyperinsulinemia, impaired
glucose tolerance, decreased insulin sensitivity, dyslipidemia and reduc-
tions in peripheral and brain glucose uptake. Importantly, HFD mice
showed cognitive deﬁcits in multiple areas, including object recogni-
tion, cued memory, and spatial learning and memory. These results
conﬁrmmultiple studieswhich have demonstrated behavioral and neu-
robiological impairments using genetic and diet-induced rodentmodels
of obesity and T2D (Gault et al., 2010; Li et al., 2002; Stranahan et al.,
2008a, 2008b; Winocur et al., 2005).
Interestingly, these cognitive impairments were not observed in a
model of T1D, as mice with STZ-induced diabetes performed these
tasks at levels similar to age-matched controls. While several studies
have demonstrated cognitive dysfunction in rodent models of T1D
(Biessels et al., 1996; Ramanathan et al., 1998; Alvarez et al., 2009;
Rajashree et al., 2011), our data is consistent with human studies
where learning and memory are generally spared in T1D patients
(Brands et al., 2005), while multiple memory deﬁcits are noted even
in the early stages of T2D (Ruis et al., 2009). It should benoted, however,
that differentialmetabolic effects have been observed depending on the
mouse strain and caloric source, i.e. high fat vs high-sucrose diets
(Surwit et al., 1995; West et al., 1995). Thus, while similar cognitive
Fig. 7. Cerebral Vessel Density is Unaltered in HFD and HFD–LFDMice. (A–C) Representative images of vascular casting within the brain. (A) Imagemontage of a full coronal brain section,
taken at 4× magniﬁcation. Red = vessels (casting agent). Blue = nuclei (DAPI). Scale bar, 2 mm. (B) Image montage of the hippocampus, taken at 10×. Scale bar, 500 μm.
(C) Representative image of the CA1 region of the hippocampus, taken at 10×. Scale bar, 100 μm. (D–E) Blood vessel volume is unaffected by MetS. The volume of blood vessels within
speciﬁc regions of the (D) prefrontal cortex (cingulate (CG), prelimbic (PL) and infralimbic (IL)) and (E) hippocampus (CA1, CA3, and dentate gyrus (DG)). Insets show representative
coronal brain sections that have been perfusedwith a ﬂuorescent casting agent. Red=vessels (casting agent). Scale bar=2mM. (F–G)Representative images from a 3D analysis of vessel
diameter and volume. (F) Physically contiguous vessels were identiﬁed and vessel diameter and volume were calculated using 4Quant software (colors correspond to vessel region and
diameter). (G) Vessel diameter and volume were calculated in a 3D stack using Amira software (color corresponds to vessel diameter). (H–I) (H) Total vessel volume and (I) number of
vessel branching points within 3D areas of the hippocampus and prefrontal cortex. (H, I ANOVA, followed by Tukey's multiple comparison test.) (n= 3–4).
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the form of either simple carbohydrates or saturated fats (Kanoski and
Davidson, 2011), it is important to point out that themetabolic and cog-
nitive effects observed in this studymay still be speciﬁc to a high fat diet.
Additionally, aswe employed only high-fat fed femalemice of advanced
age, the extent to which these data extend across sex, age and degree of
metabolic dysfunction is unclear, and further studies are needed to
elucidate these issues.
In order to examine the effects of weight loss and improvements in
metabolism on cognitive function, we subjected HFD mice to a brief,
but intensive reduction in dietary fat and caloric intake. This one
month low-fat diet intervention improved nearly every measure of pe-
ripheral metabolism and led to a complete restoration of the cognitive
deﬁcits associated with MetS. The intervention employed in this study
would be considered extreme by human standards, and although trans-
lation is difﬁcult given the differences in lifespan between mice and
humans, perhaps the most appropriate comparison is the extensive
weight loss observed in obese patients following bariatric surgery.
There is evidence of rapid improvement in memory among bariatric
surgery patients (Gunstad et al., 2011), and together with other weightloss studies reporting improvement in various cognitive domains
(Siervo et al., 2011), the data presented here suggest that the cognitive
dysfunction associated with MetS is at least partially reversible. Unfor-
tunately, a very small percentage of patients with T2Dmakes the signif-
icant lifestyle changes necessary to send the disease into remission
(Karter et al., 2014). However, recent work suggests that time restricted
feeding (Chaix et al., 2014) and intermittent fasting (Brandhorst et al.,
2015) may provide similar metabolic and/or cognitive beneﬁts, and
thus may represent more easily adoptable behavioral interventions for
obese individuals and patients with MetS or T2D.
Memory impairment as a result of neurodegeneration, as in cases of
Alzheimer's disease (AD) and Vascular Dementia (VsD) is believed to be
largely irreversible once it occurs. In general, the cognitive deﬁciencies
associated withMetS and T2D appear to occur early, perhaps in concert
with the obesity and IR which typically occur prior to overt diabetes
(Kim and Feldman, 2015; Ruis et al., 2009; Sellbom and Gunstad,
2012). The model employed here reﬂects these early stages of T2D in
humans, and it is probable that there becomes a point at which the cog-
nitive dysfunction associated with T2D becomes irreversible. For exam-
ple, there is evidence of decreased brain volume (Espeland et al., 2013)
Fig. 8. Infusion of LFD Plasma ImprovesMemory inHFDMice and isAssociatedwith aDistinctMetabolic Proﬁle. (A) Experimental design. Plasmawas collected fromage-matched LFD (LFD
plasma) or HFDmice (HFD plasma). HFD recipients were intravenously injectedwith 100 μl of pooled plasma every other day for 10 days. Twenty-four hours following the ﬁnal infusion,
plasmawas collected from recipientmice for an untargetedmetabolomics analysis. (B–C) Infusion of LFD plasma is sufﬁcient to improve cognitive function inHFDmice. HFDmice injected
with plasma collected from age-matched LFD controlmice located a hidden platform faster thanHFDmice injectedwith plasma collected from other HFDmice. Latency to platformwithin
(B) individual testing sessions and (C) daily averages (mean of two testing sessions). (D) Two-way hierarchical clustering of the 45 plasma metabolites that signiﬁcantly differ (p b 0.05)
between HFD recipient mice infusedwith LFD or HFD plasma. Color in the heatmap reﬂects the relativemetabolite abundance level, with red being higher, and blue lower, than themean
value. Colored circles denote themetabolic pathway(s) inwhich eachmetabolite plays a role. (E) A global view of themetabolomewas created using a pathway impact analysis. Theme-
tabolome view reﬂects increasing pathway impact according to the betweenness centralitymeasure, which reﬂects key nodes in pathways that have been signiﬁcantly altered by infusion
of ‘healthy’ plasma. Only pathways with a signiﬁcance of p b 0.05 are shown (above the dotted gray line). (F) Random forest (RF) prediction using globalmetabolomic expression proﬁles.
Mean decrease accuracy represents the percent decrease in accuracy of the RF analysiswhen the algorithm is performed in the absence of the indicated biomarker. The RF plot shows that
the identiﬁedmetabolites stratify the recipient mice according to donor plasma statuswith a cumulative predictive accuracy of 94%. (B, *p b 0.05, **p b 0.01 compared to HFD+HFD plas-
ma, repeatedmeasures ANOVA). (C, *p b 0.05, t-test). (n=9). (Abbreviations: ADMA, Asymmetric dimethylarginine; DG, Diacylglycerol; GlcCer, Glucosylceramide; LPA, Lysophosphatidic
acid; PC, Phosphatidylcholine; PE, Phosphatidylethanolamine; PG, Phosphatidylglycerol; PGP, phosphatidylglycerolphosphate; PI, Phosphatidylinositol; PS, Phosphatidylserine).
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thology in diabetic humans (Peila et al., 2002; Ahtiluoto et al., 2010;
Sonnen et al., 2009) and rodents (Park, 2011). In these cases, it is less
likely that a simple lifestyle intervention would signiﬁcantly improve
neurological function. Given the resistance of T2D to therapy in its latestages, it becomes critical for future studies to determine if and when
this “point of no return” occurs, and intervene with medical and public
health initiatives focused on early stages of the disease.
Some evidence suggests that inﬂammation may serve as the causa-
tive link between diabetes, cerebrovascular function and cognitive
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increased in HFD mice, a number of plasma cytokines – including
IL-12p70, IL1βF, TNFα, and IFNγ – did not signiﬁcantly differ from the
LFD or HFD–LFD groups. We did, however, observed a pronounced
change in CXCL1, a neutrophil chemoattractant with pro-angiogenic
properties (Miyake et al., 2013). Circulating CXCL1 levels were in-
creased in HFD mice, but similar to LFD levels in HFD–LFD mice.
CXCL1 crosses the blood brain barrier (BBB) (Pan and Kastin, 2001), is
elevated in patients with T2D (Sajadi et al., 2013) as well as those
with AD (Zhang et al., 2013), and thus represents a potential link be-
tween diabetes, inﬂammation, cerebrovascular function and cognition.
Along these lines, neuroprotectivemolecules such as BDNF, which is de-
creased in the serum of T2D patients (Fujinami et al., 2008), have also
been suggested as a link between diabetes and brain function. Similarly,
the neuropeptide GLP-1 and its long-lasting analogs have received
much attention in recent years due to their potential to treat T2D
(Kern et al., 2001). GLP-1 readily crosses the BBB and its receptors are
expressed in multiple brain regions (Hamilton and Hölscher, 2009).
Furthermore, treatment with GLP-1 in rodent models of several neuro-
logical disorders, including high fat fed mice (Lennox et al., 2014), has
been shown to stimulate neurogenesis (Rampersaud et al., 2012), im-
prove long-term potentiation (Gault and Hölscher, 2008), and improve
cognitive function (Lennox et al., 2014; Rachmany et al., 2013; Solmaz
et al., 2015). While we observed lower plasma GLP-1 concentrations
in HFD mice compared to both LFD and HFD–LFD mice, this difference
did not reach statistical signiﬁcance. It should be noted, however, that
the multiple plasma markers described above, in which a trend was
observed but statistical signiﬁcance was not reached, are likely due to
study limitations in power. Thus, the potential cognitive effects of
these various inﬂammatory, neurotrophic and metabolically active fac-
tors still represent plausible biological mechanisms by which both
weight loss and infusion of ‘healthy’ plasmamay exert beneﬁcial effects,
particularly if acting in concert or in parallel.
Another potential modiﬁable link between diet-induced meta-
bolic and cognitive dysfunction is the regulation of cerebral blood
ﬂow (CBF) (Barnes and Joyner, 2012). In some studies, individuals
with T2D show lower CBF (Novak et al., 2006) and a reduced ability
to maintain adequate and stable CBF compared to controls (Kim
et al., 2008). At normal physiological concentrations in the periph-
ery, insulin acts as a vasomodulator by stimulating microvascular
perfusion (Lambadiari et al., 2015). In patients with T2D, administra-
tion of intranasal insulin results in enhanced cognition whichmay be
mediated via vasoreactive effects (Novak et al., 2014). Interestingly,
evidence from coronary vessels suggests that the mechanism by
which insulin exerts its vasodilatory effects differs depending on
vessel size (Oltman et al., 2000). Our results show that improve-
ments in CBV, a measure reﬂective of vascular perfusion, following
the reduction in dietary fat content were speciﬁc to microvessels.
Themicrovascular response to insulin appears to rely heavily on cap-
illary recruitment (Shim et al., 2014; Dawson et al., 2002; Vincent
et al., 2002). In skeletal muscle and adipose tissue, the microvascula-
ture is particularly sensitive to insulin, and this sensitivity is im-
paired by obesity and IR (Belcik et al., 2015). Our data suggest that
a similar phenomenon may occur in the brain, with speciﬁc reduc-
tions in microvascular CBV during MetS and a subsequent increase
following restoration of insulin sensitivity.
Alternative to impairments in insulin-mediated vasoreactivity, the
observed decrease in microvascular CBV during MetS could be ex-
plained by structural abnormalities. Decreases in vessel density due to
microvascular rarefaction occur in several chronic diseases, including
obesity (Pasarica et al., 2009). However, both increased cerebral angio-
genesis (Ergul et al., 2014) and decreased cerebral vessel density have
been reported in diabetic rodents (Beauquis et al., 2010). While we ob-
served regional differences in capillary density, as shown by others
(Cavaglia et al., 2001),we did not observe any changes in vessel density,
of any diameter, between LFD, HFD, and HFD–LFD mice.As vascular function represents a critical link between diabetes
and cognition, it is plausible that circulating factors could affect
brain function. Experiments involving shared circulatory systems
have played a crucial role in the study of obesity and T2D
(Coleman, 2010), and a series of studies have shown that young
blood has numerous rejuvenative properties in aging mice (Villeda
et al., 2014; Ruckh et al., 2012; Salpeter et al., 2013; Loffredo et al.,
2013; Katsimpardi et al., 2014). However, these recent experiments
all highlight a dichotomy between the young and old. To the best of
our knowledge, our study represents the ﬁrst evidence that plasma
infusion also holds promise in the age-independent context of
MetS. Here, infusion of plasma collected from lean, non-diabetic
LFD donors was sufﬁcient to improve cognitive function in HFD
mice, and this improvement occurred in the face of concurrent
obesity and continued consumption of a high fat diet. These data
suggest that administration of plasma, or of speciﬁc factors found
within, may represent a potential strategy for the treatment of the
cognitive complications of diabetes.
It is unlikely that the cognitive gains observed following plasma
infusion are solely due to one factor, as recent contradictory ﬁndings
in aging studies indicate (Loffredo et al., 2013; Egerman et al., 2015).
Additionally, dilution and temporal factors likely reduce the impact
of any one individual factor; for example, HFD mice received 100 μl
infusions but have N2.5 ml total blood volume and the analysis
occurred 24 h after the ﬁnal infusion. In this regard, while our
untargeted metabolomics analysis revealed 45 signiﬁcantly altered
metabolites, the effect size of each individual factor was small (fold
change for 99% of metabolites was b2.0). Still, two main patterns of
note were revealed in HFD mice infused with ‘healthy’ LFD plasma:
lower concentrations of multiple AAs and their byproducts, and
higher concentrations of numerous GPLs. Elevated levels of branched
chain (bc) AAs are associated with obesity and IR, and are predictive
of future development of T2D (Newgard et al., 2009; Wang et al.,
2011). However, we did not observe signiﬁcant changes in bc AAs,
likely because both plasma recipient groups still had MetS. Instead,
our analysis revealed alterations in several AAs that more closely
resemble the metabolic changes that accompany aging
(Houtkooper et al., 2011). The analysis also highlighted alterations
in various classes of GPLs, particularly PEs and PCs. While it is unclear
how elevated plasma concentrations of PEs and PCs affect cognitive
function, they are present in relatively high amounts in neural
membranes where they play metabolic, structural and functional
roles (Farooqui et al., 2000). Moreover, lower levels of brain GPLs
have been associated with neurodegenerative disease (Wood et al.,
2015). Additionally, a common second messenger produced from
PEs and PCs is arachidonic acid, which was also signiﬁcantly elevated
in HFD mice receiving infusions of LFD plasma. Arachidonic acid is a
common precursor to several vasoactive eicosanoids which repre-
sent an intriguing biological link between IR, microvascular function
and cognition (Iliff et al., 2009; Shim et al., 2014). Also of interest is
asymmetric dimethylarginine (ADMA), a methylated form of L-argi-
nine, which was present in signiﬁcantly lower concentrations in HFD
mice receiving infusions of LFD plasma. ADMA has been proposed as
a potential link between vascular disease and dementia, as it is found
in higher concentrations in T2D individuals (Abbasi et al., 2001) and
inhibits nitric oxide synthesis and vasodilation (Asif et al., 2013).
Another limitation of the current study is that it remains
unknown whether the observed cognitive beneﬁts associated with
plasma infusion are a result of direct modulation of neuronal
function, secondary to peripheral metabolic changes, or a more
complicated cascade of events involving both. Despite our
observations that body weight, blood glucose and swim speed were
unchanged by plasma infusion, there remain numerous indirect
mechanisms through which the plasma infusions could modulate
brain function, including effects on general metabolism, stress
response, appetite, gut hormones, immune mediators, and vascular
40 L.A. Johnson et al. / EBioMedicine 3 (2016) 26–42function. Thus, future studies aimed at elucidating the precise
biological mechanisms underlying the cognitive beneﬁts associated
with weight loss and improvements in metabolism, as well as those
associated with plasma infusion, are critical.
In summary, this work highlights the malleable nature of diet-in-
duced cognitive dysfunction. We hope that this study will spur
future research and inspire individual lifestyle changes aimed at
preventing or ameliorating the cognitive decline associated with
obesity, IR and T2D.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.12.008.
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